Metagenomi Therapeutics Net Profit Margin 2022-2025 | MGX
Metagenomi Therapeutics net profit margin from 2022 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Metagenomi Therapeutics Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-09-30 | $0.03B | $-0.09B | -275.00% |
| 2025-06-30 | $0.04B | $-0.09B | -248.57% |
| 2025-03-31 | $0.05B | $-0.08B | -169.57% |
| 2024-12-31 | $0.05B | $-0.08B | -147.17% |
| 2024-09-30 | $0.06B | $-0.07B | -134.55% |
| 2024-06-30 | $0.06B | $-0.08B | -136.36% |
| 2024-03-31 | $0.05B | $-0.08B | -167.39% |
| 2023-12-31 | $0.04B | $-0.07B | -154.55% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.058B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $40.740B | 12.64 |
| BridgeBio Pharma (BBIO) | United States | $15.078B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.364B | 17.67 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.797B | 22.90 |
| Bausch Health Cos (BHC) | Canada | $2.136B | 1.52 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.283B | 9.24 |
| Taysha Gene Therapies (TSHA) | United States | $1.276B | 0.00 |
| Personalis (PSNL) | United States | $0.830B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.417B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.180B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |